A new review article on sirolimus in pediatric dermatology has appeared in the Indian Journal of Paediatric Dermatology. The piece, titled "Sirolimus in Pediatric Dermatology," is now indexed on the Ovid research platform and sits behind subscription paywalls.

The Indian Journal of Paediatric Dermatology serves as the field's main specialty publication in South Asia. Ovid, owned by Wolters Kluwer, distributes the article through its medical literature aggregator contracts. Hospital libraries across North America, Europe, and Asia typically carry Ovid access through institutional subscriptions. The article will reach pediatric dermatologists, fellows, and pharmacy committee members who track mTOR inhibitor safety data.

No abstract or full-text excerpt appears in the public metadata. Readers seeking the authors' analysis will need a paid Ovid login or an interlibrary loan request. Citation alerts will surface the title within days.

What does the article likely cover?

The title signals a broad survey of sirolimus use in children. Sirolimus, a macrolide first isolated from soil bacteria on Easter Island, blocks the mTOR pathway. It earned its dermatology foothold in vascular anomalies and facial angiofibromas linked to tuberous sclerosis complex. Topical formulations followed oral use as clinicians sought ways to limit systemic exposure.

Small trials and case series have since tested topical sirolimus in additional pediatric conditions. These include port-wine stains resistant to pulsed-dye laser, refractory pyogenic granulomas, and selected genodermatoses. The IJPD review likely aggregates that scattered evidence into a single clinical framework. Indian dermatology has long been a hub for vascular anomaly work, given the country's pediatric case volume.

Pediatric dermatologists treat a narrower patient population than adult specialists. Drug approvals often lag for children, leaving off-label use as the norm. A consolidated review helps practicing clinicians weigh efficacy, safety, and monitoring requirements for mTOR blockade.

What should practicing clinicians watch?

The full text should detail dosing, blood-level monitoring, and adverse event profiles. Sirolimus carries known systemic risks: mucositis, hyperlipidemia, cytopenias, and immunosuppression. Topical formulations reduce systemic exposure but require compounded preparations in most settings. Compounding pharmacies vary in formulation stability, which complicates comparative effectiveness work.

Reimbursement varies sharply by indication. FDA-approved topical sirolimus exists for facial angiofibromas of tuberous sclerosis. Off-label dermatologic uses typically require prior authorization and case-by-case payer review. Pharmacy benefit managers rarely list sirolimus on preferred formularies for dermatology indications outside transplant care.

The Indian subcontinent adds its own prescribing context. Tuberous sclerosis prevalence, formulary access, and tuberculosis-endemic regions shape sirolimus decision-making in ways Western reviews often miss. Latent tuberculosis reactivation under mTOR inhibition warrants extra vigilance. Compounded cost pressures also shape Indian prescribing in ways rarely addressed elsewhere.

What comes next?

The article will likely circulate through journal clubs and board review prep in the coming quarters. Watch for citation activity on PubMed and Google Scholar as the title enters circulation. Expect the review to inform pediatric dermatology fellowship curricula and update local hospital guidelines on mTOR inhibitor use in children over the next year.